UY36453A - Complejos radiofármacos - Google Patents

Complejos radiofármacos

Info

Publication number
UY36453A
UY36453A UY0001036453A UY36453A UY36453A UY 36453 A UY36453 A UY 36453A UY 0001036453 A UY0001036453 A UY 0001036453A UY 36453 A UY36453 A UY 36453A UY 36453 A UY36453 A UY 36453A
Authority
UY
Uruguay
Prior art keywords
chelator
forming
tissue
coupling
radiopharmacle
Prior art date
Application number
UY0001036453A
Other languages
English (en)
Inventor
Cuthbertson Alan
Original Assignee
Bayer As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54884033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY36453(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer As filed Critical Bayer As
Publication of UY36453A publication Critical patent/UY36453A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1021—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against cytokines, e.g. growth factors, VEGF, TNF, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

Método para formación de un complejo de torio dirigido a tejido que comprende; a) formar un quelante octadentado que comprende cuatro porciones hidroxipiridinona (HOPO) sustituidas con un grupo C1-C3alquilo, y una porción de acoplamiento; b) acoplar dicho quelante octadentado a al menos un péptido o proteína de direccionamiento a tejido que comprende al menos una porción amina por medio de al menos un reactivo de acoplamiento de amida para generar un quelante de direccionamiento a tejido; y c) poner en contacto dicho quelante con una solución acuosa que comprende un ion de al menos un isótopo de torio emisor alfa.
UY0001036453A 2014-12-17 2015-12-17 Complejos radiofármacos UY36453A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201422512 2014-12-17

Publications (1)

Publication Number Publication Date
UY36453A true UY36453A (es) 2016-07-29

Family

ID=54884033

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036453A UY36453A (es) 2014-12-17 2015-12-17 Complejos radiofármacos

Country Status (30)

Country Link
US (2) US20170340759A1 (es)
EP (1) EP3233137A1 (es)
JP (2) JP6821569B2 (es)
KR (1) KR20170094223A (es)
CN (1) CN107278155B (es)
AR (1) AR103063A1 (es)
AU (2) AU2015367722A1 (es)
BR (1) BR112017012841A2 (es)
CA (1) CA2970841A1 (es)
CL (1) CL2017001592A1 (es)
CO (1) CO2017005975A2 (es)
CR (1) CR20170256A (es)
CU (1) CU24493B1 (es)
DO (1) DOP2017000143A (es)
EA (1) EA201791350A9 (es)
EC (1) ECSP17038089A (es)
IL (1) IL252244B (es)
JO (1) JOP20150319B1 (es)
MA (1) MA41176A (es)
MX (1) MX2017008093A (es)
MY (1) MY194190A (es)
NI (1) NI201700076A (es)
PE (2) PE20171181A1 (es)
PH (1) PH12017501125A1 (es)
SG (1) SG11201704917XA (es)
TN (1) TN2017000255A1 (es)
TW (1) TWI654179B (es)
UA (1) UA125369C2 (es)
UY (1) UY36453A (es)
WO (1) WO2016096843A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017239018A1 (en) * 2016-03-24 2018-08-16 Bayer As Radio-pharmaceutical complexes
SG11201810967VA (en) * 2016-06-10 2019-01-30 Bayer Pharma AG Radio-pharmaceutical complexes
EP3585436A1 (en) * 2017-02-24 2020-01-01 Bayer AS Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
CN110573186A (zh) * 2017-03-30 2019-12-13 康奈尔大学 发射α的放射性核素的大环配合物及其在癌症的靶向放射治疗中的应用
EP3843743A1 (en) 2018-08-28 2021-07-07 Bayer AS Combination of pi3k-inhibitors and targeted thorium conjugates
EP3927374A1 (en) 2019-02-21 2021-12-29 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates
EP3927339A1 (en) 2019-02-22 2021-12-29 Bayer Aktiengesellschaft Combination of ar antagonists and targeted thorium conjugates
AR119479A1 (es) 2019-07-25 2021-12-22 Bayer As Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer
TW202216771A (zh) 2020-06-26 2022-05-01 德商拜耳廠股份有限公司 用於治療應用之ccr8抗體
AU2022210371A1 (en) 2021-01-22 2023-07-20 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2104662A2 (en) * 2007-01-11 2009-09-30 GE Healthcare AS Chelating agents
GB201002508D0 (en) * 2010-02-12 2010-03-31 Algeta As Product
GB201208309D0 (en) * 2012-05-11 2012-06-27 Algeta As Complexes

Also Published As

Publication number Publication date
CR20170256A (es) 2017-08-11
TN2017000255A1 (en) 2018-10-19
ECSP17038089A (es) 2017-07-31
US20210322583A1 (en) 2021-10-21
BR112017012841A2 (pt) 2018-04-10
CL2017001592A1 (es) 2018-03-16
PE20230829A1 (es) 2023-05-19
TWI654179B (zh) 2019-03-21
MY194190A (en) 2022-11-18
JOP20150319B1 (ar) 2021-08-17
CO2017005975A2 (es) 2017-11-30
TW201627286A (zh) 2016-08-01
SG11201704917XA (en) 2017-07-28
IL252244A0 (en) 2017-07-31
AR103063A1 (es) 2017-04-12
EP3233137A1 (en) 2017-10-25
DOP2017000143A (es) 2017-07-15
PH12017501125A1 (en) 2017-11-27
CA2970841A1 (en) 2016-06-23
UA125369C2 (uk) 2022-03-02
AU2021202665A1 (en) 2021-05-27
IL252244B (en) 2020-10-29
CU24493B1 (es) 2020-12-17
CU20170082A7 (es) 2017-10-05
MA41176A (fr) 2017-10-24
KR20170094223A (ko) 2017-08-17
WO2016096843A1 (en) 2016-06-23
NI201700076A (es) 2017-09-22
US20170340759A1 (en) 2017-11-30
EA201791350A9 (ru) 2020-02-11
CN107278155A (zh) 2017-10-20
JP2021063108A (ja) 2021-04-22
CN107278155B (zh) 2021-03-30
AU2021202665B2 (en) 2023-04-27
PE20171181A1 (es) 2017-08-22
JP6821569B2 (ja) 2021-01-27
MX2017008093A (es) 2018-02-09
JP7160961B2 (ja) 2022-10-25
JP2018506513A (ja) 2018-03-08
AU2015367722A1 (en) 2017-06-08
EA201791350A1 (ru) 2017-12-29

Similar Documents

Publication Publication Date Title
UY36453A (es) Complejos radiofármacos
BR112018075554A2 (pt) complexos radiofarmacêuticos
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
CY1123358T1 (el) Υδατικο φαρμακευτικο σκευασμα που περιεχει αντισωμα αντι-pd-1 αβελουμαμπη
AR085665A1 (es) Fluidos de tratamiento que contienen un agente quelante biodegradable y metodos para su uso
BR112016006397A2 (pt) formulações de anticorpo de anti-pdl1
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
GT201700185A (es) Inhibidores selectivos de bace1
BR112019000026A2 (pt) sais de ácido diorganilfosfínico, método para sua produção e seu uso
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112017006602A2 (pt) método de conjugação de um polipeptídeo
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
AR105967A1 (es) Sales de un inhibidor de pim quinasa
BR112018003331A2 (pt) sondas para imagear proteína huntingtina
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
BR112018071519A2 (pt) técnicas para avaliação comparativa de estratégias de pareamento em um sistema de centro de contato
EA201790408A1 (ru) Зонды для визуализации белка хантингтина
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
BR112019000135A2 (pt) formulações de anticorpo
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo
MX2019002818A (es) Metodos para detectar anticuerpos neutralizantes anti-leptina.
BR112018007551A2 (pt) método para detectar anticorpos neutralizantes contra insulina humana recombinante em soro humano
CO2017007061A2 (es) Método de detección de la enteritis necrótica aviar
CO2018005151A2 (es) Solución acuosa de peróxido de hidrógeno que comprende un estabilizante específico

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230626